Yondelis 1 mg Yondelis Generic Content-Trabectedin also known as ecteinascidin, Manufactured By : Janssen Pharmaceutica, Belgium Yondelisis an anti-tumor drug. Yondelis is approved for the treatment of advanced soft tissue sarcoma.
Taken into use in the treatment or cure of adult patients with higher soft tissue sarcoma, following failure of ifosfamide and anthracyclines, or who are unsuitable to be given these agents, Yondelis (also recognized as Ecteinascidin 743 or ET-743 or Trabectedin) is a famous anti-tumor drug. Efficiency data depends largely on leiomyosarcoma and liposarcoma patients. This in blend with pegylated liposomal doxorubicin (PLD) is used for the treatment of people suffering with relapsed platinum-sensitive ovarian cancer. Johnson and Johnson, and Zeltia manufacture the medication under the brand Yondelis.
The U.S. Food and Drug Administration (FDA) and the European Commission have approved orphan drug class to trabectedin for ovarian cancer and soft tissue sarcomas.
Medications and their probable side effects can influence certain people in dissimilar ways. Below are listed some of the common side effects that are identified to be associated with the usage of this medicine. Just as a side effect is confirmed, here does not mean that all individuals using this medicine will feel or go through that or any side effect.
Import License No. FF-116-15404 for 1 vial, Inclusive of all taxes
Imported & Marketed in India by
30, Forjett Street, Mumbai 400036